Navigation Links
Atlas Appoints David Whitaker as Operations Director
Date:11/27/2013

BATH, England, November 27, 2013 /PRNewswire/ --

Atlas Genetics Ltd ("Atlas" or the "Company"), a diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases, today announces the appointment of David Whitaker as Operations Director with immediate effect.

David joins Atlas from DNA Electronics, where he worked as Manufacturing & Mechanical Engineering Manager, responsible for the development of a fully portable, point-of-care genetic test device.  This project involved a wide range of technical disciplines including microfluidics, electronics and molecular biology.  He worked closely with the acting Chief Scientific Officer on the overall management of the project and held direct responsibility for all device engineering activities.  

Prior to this, he spent five years as a Principal Consultant in PA Consulting's Technology and Innovation Practice.  During his tenure, he successfully developed and patented a range of medical devices for both big pharma and start-up companies.  Before joining PA Consulting, David worked in a variety of medical device engineering, contract engineering and consulting positions at companies including Ivax Pharmaceuticals, Futura Medical West Pharmaceuticals and Risdon Pharma.

David has First Class BEng degree in Mechanical & Manufacturing Engineering with Management from the University of Leeds.

Dr John Clarkson, Chief Executive Officer of Atlas, commented: "At Atlas, we have worked hard over the past year to enhance and develop our senior management team.  David brings considerable operational expertise which will be important as we enter a new phase of product manufacture and growth, further progressing Atlas towards becoming a first class diagnostics company."

About Atlas (http://www.atlasgenetics.com)

Atlas (Atlas Genetics Ltd) develops ultra-rapid point-of-care (POC) diagnostic tests for infectious diseases.  The Atlas io™ system uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability.  The Company has its head office and laboratory facilities near Bath.  Atlas was established in 2005 and is financed by VC, corporate and private investors including Consort Medical plc, Novartis Venture Funds, J&J Development Corporation, Life Science Partners (LSP), BB Biotech Ventures and YFM Equity Partners.  The company raised £16.9 million in series B finance in 2011.

The Atlas io™ platform

POC diagnostics offer health professionals the ability to test for medical conditions at the site of patient care.  Atlas has developed the io™ system, a flexible POC technology platform, which has been designed to accurately and quickly diagnose a wide range of medical conditions within 30 minutes.  The Atlas io™ system consists of an inexpensive test machine into which a disposable cartridge containing a patient sample is inserted.  The io™ platform is scheduled for clinical trials in 2014, followed by rollout in Europe and the United States, pending regulatory approvals.

Atlas is developing tests for a range of infectious diseases including sexually transmitted infections and hospital acquired infections.  The io™ system will initially be launched for the rapid testing of Chlamydia, allowing clinicians to test and treat patients in a single visit.  Around 40 million tests are carried out for these diseases in Europe and the US every year.  According to the European Centre for Disease Prevention and Control, Chlamydia is the most frequently reported bacterial Sexually Transmitted Infection (STI), with prevalence rates in young people between 5-10%, whilst Gonorrhoea is the second most commonly 'reported' STI.  An increasing awareness, number of reported cases and increased testing for Gonorrhoea, Trichomonasvaginalis and Mycoplasma genitalium infection means these are a logical extension to the STI test menu for the io™ platform.  The worldwide in vitro diagnostic market for infectious disease testing is estimated to be worth around US$9 billion.

Contact details:

Atlas Genetics Ltd:    
John Clarkson    
Tel: +44(0)1225-717930
   
FTI Consulting:    
Mo Noonan / Ben Atwell    
Tel: +44(0)207-831-3113



'/>"/>
SOURCE Atlas Genetics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Roka Bioscience Atlas System For Food Pathogen Detection Integrated At Department of Defense Food Analysis and Diagnostic Laboratory
2. Proteome atlas for the tuberculosis pathogen
3. Quadrant Engineering Plastic Products Assigns Production of Acetron® GP and Nylon 101 Hex/Square Rods to Atlas Fibre Company
4. Cancer Antibodies: Drug Target Atlas and Competitive Outlook
5. Roka Bioscience Kicks Off Atlas on Tour, a Mobile Demonstration Vehicle for the Food Safety Industry, at IAFP
6. CMDBioscience Appoints Tomi Sawyer to Scientific Advisory Board; Entrepreneurial Drug Hunter and Distinguished Scholar Named as Founding Chair
7. Boston Biomedical Appoints Patricia S. Andrews as Chief Commercial Officer
8. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
9. Convoy Therapeutics Appoints Clinical Advisory Board
10. Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
11. Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy ... and perspectives by leading experts on the unique regulatory challenges of stem cell ...
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... The first ... took 20 years until the first data on cross-contamination of human cell lines with ... been an increasing issue in cell culture labs and is associated with dramatic consequences ...
(Date:6/22/2017)... ... ... Charm Sciences, Inc. is pleased to announce that its Charm Amphenicol (AMPH) test ... screening test at dairies and farms for raw commingled cow milk. The test was ... system. These systems are a combination incubator and reader in one. , “The AMPH ...
(Date:6/20/2017)... Florida (PRWEB) , ... June 20, 2017 , ... Biologist ... in men. While researching her latest book, Men Chase, Women Choose: The Neuroscience of ... that love has a physiological effect on men. ”The logical next step, in my ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):